News
-
-
-
PRESS RELEASE
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
Sanofi and Regeneron announce positive results from Dupixent pivotal study in allergic fungal rhinosinusitis, with sBLA accepted for FDA priority review -
PRESS RELEASE
Press release: Q3: continued sales and earnings progress
-
-
PRESS RELEASE
Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
Sanofi's Tzield accepted for expedited review by FDA under National Priority Voucher pilot program to delay progression of stage 3 type 1 diabetes. Breakthrough therapy with significant unmet medical need addressed -
-
PRESS RELEASE
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
New phase 2 data presented at ESMO Congress highlight AlphaMedix as a promising targeted alpha therapy for GEP-NETs, showing high response rates and potential to address unmet medical needs -
-
PRESS RELEASE
Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
Sanofi's high-dose influenza vaccine Efluelda/Fluzone High-Dose shows superior protection for older adults by reducing hospitalizations. FLUNITY-HD study details robust evidence published in The Lancet
